TerminatedPhase 2NCT00429533
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
Studying Pemphigus vulgaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jacobus Pharmaceutical
- Principal Investigator
- Victoria P. Werth, MDUniversity of Pennsylvania
- Intervention
- Dapsone(drug)
- Enrollment
- 48 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 1996 – 2004
Study locations (8)
- Northwestern University Medical Center, Chicago, Illinois, United States
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Cooper Hospital/University Medical Center, Camden, New Jersey, United States
- The New York VA Medical Center, New York University, New York, New York, United States
- Case Western Reserve University School of Medicine, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00429533 on ClinicalTrials.govOther trials for Pemphigus vulgaris
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07384221Periodontal Status and Disease Severity in Pemphigus Vulgaris PatientsSaglik Bilimleri Universitesi
- RECRUITINGPHASE1, PHASE2NCT04422912A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)Cabaletta Bio
- RECRUITINGNCT02753777Autoimmune Blistering Diseases StudyUniversity of Pennsylvania